Amgen Inc (AMGN) 158.56 $AMGN
Final Glance: Biotechnology companies
AP - 1 hr 42 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 43 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
Amgen-Celimmune Tie Up for Autoimmune Disorder Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 3:10PM CST
Amgen Inc. (AMGN) and Celimmune have inked a deal for the development of an anti-IL-15 monoclonal antibody, AMG 714.
CYTK: 7.97 (+0.10), ANIP: 66.86 (-3.89), HZNP: 20.97 (+0.46), AMGN: 158.56 (-1.07)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 384.61 (-1.04), BIIB: 412.79 (-3.00), FB: 79.60 (-0.15), AMGN: 158.56 (-1.07), H: 61.26 (-0.50), INTC: 34.10 (+0.04), PCLN: 1,242.03 (-7.37), CELG: 118.47 (-1.84), SBUX: 94.00 (-0.22), GILD: 102.79 (-1.04), MSFT: 43.28 (-0.60), AAPL: 129.36 (+0.27), CSCO: 29.54 (-0.65), ONNN: 12.87 (-0.29)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 66.45 (+2.87), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 23.15 (+0.43), EBS: 28.87 (-1.23), AMGN: 158.56 (-1.07), BMY: 61.92 (-0.38), AZN: 68.28 (-0.45), CCXI: 7.84 (-0.28), ATHX: 2.91 (-0.04), CELGZ: 3.23 (+0.06)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.09 (+0.15), VIVO: 20.00 (-0.04), PETS: 15.13 (-0.32), PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), MSA: 49.71 (-0.47), PDLI: 7.02 (+0.01), BAX: 69.42 (-0.54), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), STJ: 67.60 (-0.76), TRIB: 18.43 (+0.46), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), THRX: 19.56 (+0.34), SNY: 48.08 (-0.21)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 412.79 (-3.00), AMGN: 158.56 (-1.07)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 234.86 (-0.94), ACET: 21.06 (-0.42), ABT: 47.09 (-0.13), AUXL: 36.47 (-0.06), ALXN: 182.51 (-2.11), AMGN: 158.56 (-1.07), BMY: 61.92 (-0.38), AMRI: 17.19 (+0.14)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.21%
Comtex SmarTrend(R) - Mon Mar 02, 3:50PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.62 to a high of $159.90. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $159.40 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.56 (-1.07)
Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data
PR Newswire - Mon Mar 02, 3:30PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 15 abstracts, including data evaluating RepathaTM (evolocumab), an investigational cholesterol-lowering medication, and Corlanor® (ivabradine), an investigational drug for chronic heart failure, at the upcoming American College of Cardiology's 64th Annual Scientific Session (ACC.15), being held March 14-16 in San Diego.
AMGN: 158.56 (-1.07)
Ligand up on Kyprolis study
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:05PM CST
AMGN: 158.56 (-1.07), LGND: 66.45 (+2.87)
Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit
PR Newswire - Mon Mar 02, 3:01PM CST
Amgen (NASDAQ: AMGN) today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta Delivery Kit includes a specially designed single-use prefilled syringe co-packaged with the new On-body Injector for Neulasta. The Neulasta Delivery Kit will enable the healthcare provider (HCP) to initiate administration of Neulasta on the same day as cytotoxic chemotherapy - with delivery of the patient's full dose of Neulasta the day following chemotherapy administration, consistent with the Neulasta prescribing information (PI).1,2
AMGN: 158.56 (-1.07)
Of Proteasome Inhibitors And PAINs
Derek Lowe - Seeking Alpha - Mon Mar 02, 2:49PM CST
Amgen is out with some new data that might well justify their purchase of Onyx a year and a half ago. A big driver for that deal was the proteasome inhibitor Kyprolis (carfilzomib) , and the company just reported results in a...
AMGN: 158.56 (-1.07)
Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Mar 02, 2:02PM CST
Amgen's (AMGN) Kyprolis met the primary endpoint in the head-to-head study.
ALNY: 106.91 (+1.51), ISIS: 68.66 (+1.86), AMGN: 158.56 (-1.07), THRX: 19.56 (+0.34)
Amgen: Blood cancer drug Kyprolis beats rival's in study
BY LINDA A. JOHNSON - AP - Mon Mar 02, 12:19PM CST
Biotech drugmaker Amgen Inc.'s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company.
AMGN: 158.56 (-1.07)
Midday Glance: Biotechnology companies
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Early Glance: Biotechnology companies
AP - Mon Mar 02, 10:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), CBAY: 7.74 (-0.61), NVS: 99.06 (-1.01)
Final Glance: Biotechnology companies
AP - 1 hr 42 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - 2 hrs 43 mins ago
BIIB: 412.79 (-3.00), GILD: 102.79 (-1.04), PFE: 34.56 (-0.21), MRK: 58.34 (-0.24), AMGN: 158.56 (-1.07), ABBV: 59.62 (-0.84), GSK: 47.71 (-0.22), BMY: 61.92 (-0.38), HSP: 87.71 (+0.04), NVS: 99.06 (-1.01), CELG: 118.47 (-1.84)
Amgen-Celimmune Tie Up for Autoimmune Disorder Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 3:10PM CST
Amgen Inc. (AMGN) and Celimmune have inked a deal for the development of an anti-IL-15 monoclonal antibody, AMG 714.
CYTK: 7.97 (+0.10), ANIP: 66.86 (-3.89), HZNP: 20.97 (+0.46), AMGN: 158.56 (-1.07)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 384.61 (-1.04), BIIB: 412.79 (-3.00), FB: 79.60 (-0.15), AMGN: 158.56 (-1.07), H: 61.26 (-0.50), INTC: 34.10 (+0.04), PCLN: 1,242.03 (-7.37), CELG: 118.47 (-1.84), SBUX: 94.00 (-0.22), GILD: 102.79 (-1.04), MSFT: 43.28 (-0.60), AAPL: 129.36 (+0.27), CSCO: 29.54 (-0.65), ONNN: 12.87 (-0.29)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 66.45 (+2.87), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 23.15 (+0.43), EBS: 28.87 (-1.23), AMGN: 158.56 (-1.07), BMY: 61.92 (-0.38), AZN: 68.28 (-0.45), CCXI: 7.84 (-0.28), ATHX: 2.91 (-0.04), CELGZ: 3.23 (+0.06)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.09 (+0.15), VIVO: 20.00 (-0.04), PETS: 15.13 (-0.32), PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), MSA: 49.71 (-0.47), PDLI: 7.02 (+0.01), BAX: 69.42 (-0.54), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), STJ: 67.60 (-0.76), TRIB: 18.43 (+0.46), TEVA: 56.46 (-0.70), ABBV: 59.62 (-0.84), THRX: 19.56 (+0.34), SNY: 48.08 (-0.21)
Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success, New Report Launched
M2 - Tue Mar 03, 5:18AM CST
Market Research Reports, Inc. has announced the addition of "Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success" research report to their website http://www.MarketResearchReports.com
BIIB: 412.79 (-3.00), AMGN: 158.56 (-1.07)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 234.86 (-0.94), ACET: 21.06 (-0.42), ABT: 47.09 (-0.13), AUXL: 36.47 (-0.06), ALXN: 182.51 (-2.11), AMGN: 158.56 (-1.07), BMY: 61.92 (-0.38), AMRI: 17.19 (+0.14)
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.21%
Comtex SmarTrend(R) - Mon Mar 02, 3:50PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.62 to a high of $159.90. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $159.40 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 158.56 (-1.07)
Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data
PR Newswire - Mon Mar 02, 3:30PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 15 abstracts, including data evaluating RepathaTM (evolocumab), an investigational cholesterol-lowering medication, and Corlanor® (ivabradine), an investigational drug for chronic heart failure, at the upcoming American College of Cardiology's 64th Annual Scientific Session (ACC.15), being held March 14-16 in San Diego.
AMGN: 158.56 (-1.07)
Ligand up on Kyprolis study
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:05PM CST
AMGN: 158.56 (-1.07), LGND: 66.45 (+2.87)
Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit
PR Newswire - Mon Mar 02, 3:01PM CST
Amgen (NASDAQ: AMGN) today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta Delivery Kit includes a specially designed single-use prefilled syringe co-packaged with the new On-body Injector for Neulasta. The Neulasta Delivery Kit will enable the healthcare provider (HCP) to initiate administration of Neulasta on the same day as cytotoxic chemotherapy - with delivery of the patient's full dose of Neulasta the day following chemotherapy administration, consistent with the Neulasta prescribing information (PI).1,2
AMGN: 158.56 (-1.07)
Of Proteasome Inhibitors And PAINs
Derek Lowe - Seeking Alpha - Mon Mar 02, 2:49PM CST
Amgen is out with some new data that might well justify their purchase of Onyx a year and a half ago. A big driver for that deal was the proteasome inhibitor Kyprolis (carfilzomib) , and the company just reported results in a...
AMGN: 158.56 (-1.07)
Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Mar 02, 2:02PM CST
Amgen's (AMGN) Kyprolis met the primary endpoint in the head-to-head study.
ALNY: 106.91 (+1.51), ISIS: 68.66 (+1.86), AMGN: 158.56 (-1.07), THRX: 19.56 (+0.34)
Amgen: Blood cancer drug Kyprolis beats rival's in study
BY LINDA A. JOHNSON - AP - Mon Mar 02, 12:19PM CST
Biotech drugmaker Amgen Inc.'s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company.
AMGN: 158.56 (-1.07)
Midday Glance: Biotechnology companies
AP - Mon Mar 02, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Early Glance: Biotechnology companies
AP - Mon Mar 02, 10:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 102.79 (-1.04), AMGN: 158.56 (-1.07), CELG: 118.47 (-1.84)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.56 (-0.21), AMGN: 158.56 (-1.07), GSK: 47.71 (-0.22), AZN: 68.28 (-0.45), MRK: 58.34 (-0.24), CBAY: 7.74 (-0.61), NVS: 99.06 (-1.01)
